[Retracted] The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia

Table 3

Self-comparison of the two groups before and after treatment.

	Time	BUN (mmol/L)	CR (μmol/L)	eGFR (ml/min/1.73 m^2)	UA (μmol/L)	Urine microalbumin/CR (mg/g)	Urine NGAL/CR (μg/g)	Urine KIM-1/CR (μg/g)
Febuxostat (n = 25)	Baseline	5.9 ± 1.9	80.7 ± 19.6	99 ± 14	555 ± 81	50 ± 15	12.1 ± 2.4	2.4 ± 0.5
	3 months	5.7 ± 2.0	77.6 ± 24.5	103 ± 17	319 ± 98	24 ± 8	6.7 ± 2.5	1.2 ± 0.3
	value	0.719	0.624	0.368	<0.001	<0.001	<0.001	<0.001
Control (n = 20)	Baseline	6.1 ± 1.9	78.1 ± 24.7	102 ± 13	570 ± 82	48 ± 18	13.8 ± 4.1	2.6 ± 0.6
	3 months	6.0 ± 2.1	78.0 ± 26.3	100 ± 15	568 ± 89	45 ± 17	14.5 ± 4.2	2.8 ± 0.7
	value	0.945	0.990	0.655	0.942	0.591	0.597	0.338